



Minutes – ENCePP Steering Group meeting

11 February 2026, 2:00–3:30 pm CET

Chairs: Helga Gardarsdottir (Utrecht University) & Catherine Cohet (EMA)

Attendees: Alejandro Arana, Annalisa Landi, Christos Kontogiorgis, K. Arnold Chan, Marco Tuccori, Melissa Kampman, Nadia Amaouche, Frauke Naumann-Winter, Susan Sandler, Thomas Goedecke, Vera Ehrenstein

Excused: Hedvig Nordeng, Laura Pizzi, Carla Torre, Gianluca Trifirò, Iryna Vlasenko, Hui-Lee Wong

EMA: Patrice Verpillat, Julianna Fogd

Topic	Speaker(s)	Objective	Indicative timing
1. <ul style="list-style-type: none"> Connection time & adoption of the agenda New SG members: welcome to Susan Sandler¹ and Helle Gerda Olsen² 	Helga & Catherine	<ul style="list-style-type: none"> Endorsement Information 	10'
2. ENCePP Plenary: feedback from the SG	All SG members	Discussion	10'
3. Working Groups and Special Interest Groups: progress update	Helga & Catherine (on behalf of the groups)	Information (decision if needed)	40'
4. Roundtable: reflection on last year of the 2024-2026 mandate of the SG	All SG members	Discussion	25'
5. Next SG meeting & A.O.B	All SG members	/	5'

1. Johnson & Johnson, representing industry

2. Danish Medicines Agency (DKMA), representing the [Heads of Medicines Agencies](#) (HMA)



1. Welcome of new members

The SG co-chairs opened the meeting and introduced the new SG members: Susan Sandler (Johnson & Johnson) representing industry, and Helle Gerda Olsen (Danish Medicines Agency), representing the [Heads of Medicines Agencies](#) (HMA).

2. ENCePP Plenary: feedback from the SG

As this was the first SG meeting since the December 2025 ENCePP Plenary, the SG members shared feedback about the meeting. It was noted that participation was decreasing compared to previous years. Some SG members suggested to organise the meeting earlier in the year, as November/December are generally busy, and to dedicate even more time to discussion and networking vs. presentations.

3. Working Groups and Special Interest Groups: progress update

The SIG and WG co-chairs were asked to share a short progress report of their activities before the SG meeting (see [Working Groups and Special Interest Groups](#)). Updates were sent to the Secretariat by the following groups: Communications and outreach; Revision of the ENCePP Guide; Diversity and Health Equity; Pragmatism in Clinical Trials; and publications in PDS.

The SG reviewed the [available updates](#). Key points include:

- Suggestion to invite the co-chairs of the WG on Communications and Outreach to the next SG meeting to discuss communication across all groups, which also requires collaboration with the SG.
- Revision of the ENCePP Guide on Methodological Standards in Pharmacoepidemiology: the Guide will be a living document, to be updated on an ongoing basis as chapter updates are delivered by authors. It was noted that the strategy for the update should be clearly defined.
- WG - Diversity and Health Equity: additional plans for conferences abstracts (ISPE, ISPOR).
- SIG - Pragmatism in Clinical Trials: perspective from industry (e.g., through survey) would be valuable; SG to discuss with the SIG co-chairs on how to proceed. Recommendations to be delivered by the group should align with the timelines of the Methodology Working Party workplan.
- SIG - Publication of selected chapters of the ENCePP Guide in PDS and Value in Health: publication series is on track except for the topic on "Research question and assessing feasibility" (Chapter 2). The final deadline from the two journals for submission is mid-March, to avoid any further delays in publication of the series. Alejandro Arana and Christos Kontogiorgis expressed interest in drafting. They will inform Helga Gardarsdottir, the lead of this SIG, as soon as possible on feasibility, given the short timeframe (submission mid-March).
- The WG on Real-World-Data (RWD) sources in non-interventional studies will be split into 8 sub-groups to better organise the work.
- General comment: the WG and SIG co-chairs should contact the SG / SG co-chairs for any questions, doubts, feedback.

4. Roundtable: reflection on last year of the 2024-2026 mandate of the SG

Catherine Cohet asked the SG to reflect on its work since the start of the mandate. It was appreciated that significant changes had been implemented, especially with the creation of the new WGs and SIGs. The aspect of variable contribution to SG meetings and overall work was raised. Discussion was initiated by the co-chairs about the continued value of ENCePP in the current European and international environment in pharmacoepidemiology, pharmacovigilance, and RWE, and related guidance and tools which are now largely available beyond ENCePP. This discussion will be continued in upcoming SG meetings.

5. Next SG meeting & A.O.B

The next meeting will be on 30 April.